Beyond The Horizon: The Predictive Power Of FOXA2 And Microrna-590 Expression

Authors

  • Zahraa Abdulkadhim Saddam Author
  • Rana Majeed Hameed Author
  • Zahraa Sabbar Omran Author

DOI:

https://doi.org/10.64252/gk1t7357

Keywords:

FOXA2, Fold Change, Ovarian Cancer, FIGO Stage

Abstract

This case-control study aimed to investigate the diagnostic and prognostic potential of FOXA2 and MicroRNA-590 (specifically its fold change) in ovarian cancer, correlating their expression levels with disease stage and grade. The study included 70 ovarian cancer patients and 35 healthy controls, conducted from October 2024 to September 2025 at from oncology unite in imam Al-Hussein Medical city & imam Al-Hassan Al-Mujtaba Hospital in Kerbala city. Sociodemographic, clinical, and biomarker data were collected via a structured questionnaire, and statistical analysis was performed using Graphical Pad Prism 9.

Demographic analysis of the patient cohort (N=70) revealed that the majority were aged 46-60 years (52.9%), obese (67.1%), housewives (88.5%), and resided in Kerbala (57.1%). A high proportion presented with Stage 4 disease (60%) and high-grade tumors (67.1%), with most receiving chemotherapy (88.5%) and exhibiting metastasis (77.1%).

Comparing biomarker levels between ovarian cancer patients and healthy controls, a statistically significant decrease was observed for both FOXA2 (patients: 3.09±1.98 vs. controls: 3.72±3.03, p=0.025) and MicroRNA-590 Fold Change (patients: 2606.50±1200.64 vs. controls: 4788.31±2223.37, P=0.009). Further analysis across disease stages indicated that MicroRNA-590 Fold Change was lowest in early-stage (Stage 1&2: 104±183) and increased in later stages (Stage 3&4: 3148±4451), though remaining significantly lower than controls (10085±12070). FOXA2 levels Were also Lower in patients Compared to controls, with a slight decrease from early (3.1±1.4) to late stages (2.9±1.1). Regarding tumor grade, FOXA2 Levels Were significantly lower in High-Grade Tumors (2.7±0.85) compared to low-grade tumors (3.3±1.5) and controls (5.2±3.9, p=0.003). MicroRNA-590 Fold Change was lowest in low-grade tumors (1340±955), higher in high-grade tumors (3451±1750), and highest in controls (10085±9070, P=0.05).

These Findings suggest That FOXA2 and MicroRNA-590 Fold Change are Significantly altered in Ovarian Cancer patients, correlating with disease Stage and Grade. This downregulation supports their potential as valuable diagnostic and prognostic biomarkers for Ovarian Cancer.

Downloads

Download data is not yet available.

Downloads

Published

2025-07-02

Issue

Section

Articles

How to Cite

Beyond The Horizon: The Predictive Power Of FOXA2 And Microrna-590 Expression. (2025). International Journal of Environmental Sciences, 408-415. https://doi.org/10.64252/gk1t7357